ArticleFrontiers in oncology2026
Proteomics and transcriptomics reveal molecular subtypes and biomarkers of advanced cutaneous T-cell lymphoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cutaneous T-cell lymphomas (CTCL) are a group of non-Hodgkin T-cell lymphomas, with mycosis fungoides and Sézary syndrome being the most common subtypes. Advanced-stage CTCL are typically aggressive, exhibiting interpatient heterogeneity in treatment response and prognosis. The underlying pathogenesis remains incompletely elucidated, posing challenges for the selection of appropriate therapies. Methods: We obtained tumor cell-enriched regions of 33 advanced CTCL samples from 31 patients using laser capture microdissection, followed by integrated proteomic and transcriptomic profiling. Selected biomarkers were further validated via immunohistochemistry. Results: We identified three molecular subtypes of advanced CTCL, which exhibited significant differences in clinical phenotypes, signature proteins, and pathways. These subtypes were designated as intracellular signaling subtype, metabolic subtype, and extracellular matrix remodeling subtype, respectively. Within intracellular signaling subtype, the PI3K-AKT-mTOR pathway was characteristically upregulated, and we found the expression level of phospho-AKT was associated with response to PI3Kδ inhibitor therapy. Comparative proteomic analysis of patients with varying treatment responsiveness and disease progression identified CTSB, GSTO1, and WDFY4 as potential biomarkers for predicting treatment responsiveness, and GOLGA1 and STIP1 as potential biomarkers for progression prediction. Conclusion: This study explored a potential molecular subtyping framework for advanced-stage CTCL associated with different clinical phenotypes. Our findings provided preliminary evidence suggesting that certain biomarkers may be associated with treatment response to PI3K inhibitors. Additionally, we screened and preliminarily identified candidate biomarkers that may be associated with treatment responsiveness and progression risk, which may assist clinicians in the management of advanced-stage CTCL. Notably, these molecular differences may also correlate with clinical characteristics and require validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.